结直肠癌中 EGFR 阻断耐药：液体活检和潜在亚克隆。
Resistance to EGFR blockade in colorectal cancer: liquid biopsies and latent subclones.
机构信息
Broad Institute of Harvard and the Massachusetts Institute of Technology, 7 Cambridge Center, Cambridge, MA 02142, USA.
出版信息
Cell Res. 2013 Jan;23(1):13-4. doi: 10.1038/cr.2012.115. Epub 2012 Jul 31.
Abstract
Two recent papers identify KRAS activation as a mechanism of acquired resistance to EGFR blockade in colorectal cancer. In doing so, they suggest that resistance to single-agent EGFR blockade will be unavoidable because these alterations exist as latent subclones within the tumor even prior to the initiation of therapy.
摘要
最近有两篇论文指出，KRAS 激活是结直肠癌对 EGFR 阻断获得性耐药的一种机制。这样一来，他们认为，由于这些改变在治疗开始之前就已经作为肿瘤内的潜伏亚克隆存在，因此对单药 EGFR 阻断的耐药将是不可避免的。
相似文献
1
Resistance to EGFR blockade in colorectal cancer: liquid biopsies and latent subclones.结直肠癌中 EGFR 阻断耐药：液体活检和潜在亚克隆。
Cell Res. 2013 Jan;23(1):13-4. doi: 10.1038/cr.2012.115. Epub 2012 Jul 31.
2
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.结直肠癌中 KRAS 突变的出现和抗 EGFR 治疗的获得性耐药。
Nature. 2012 Jun 28;486(7404):532-6. doi: 10.1038/nature11156.
3
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.结直肠癌中针对 EGFR 阻断的获得性耐药的分子进化。
Nature. 2012 Jun 28;486(7404):537-40. doi: 10.1038/nature11219.
4
The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies.在暴露于表皮生长因子受体（EGFR）单克隆抗体之前，KRAS野生型结直肠癌中从未检测到S492R表皮生长因子受体胞外域突变。
Cancer Biol Ther. 2013 Dec;14(12):1143-6. doi: 10.4161/cbt.26340. Epub 2013 Sep 23.
5
KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines.KRAS p.G13D 突变与结直肠癌细胞系对抗 EGFR 抗体治疗的敏感性相关。
J Cancer Res Clin Oncol. 2013 Feb;139(2):201-9. doi: 10.1007/s00432-012-1319-7. Epub 2012 Sep 27.
6
Anti-EGFR therapy in colorectal cancer: how to choose the right patient.结直肠癌的抗 EGFR 治疗：如何选择合适的患者。
Curr Drug Targets. 2009 Oct;10(10):1033-40. doi: 10.2174/138945009789577891.
7
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.KRAS状态及表皮生长因子受体靶向治疗对转移性结直肠癌的影响
Nat Rev Clin Oncol. 2009 Sep;6(9):519-27. doi: 10.1038/nrclinonc.2009.111. Epub 2009 Jul 28.
8
Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.结直肠癌患者对抗 EGFR 药物疗效的分子预测因子。
Curr Cancer Drug Targets. 2010 Feb;10(1):68-79. doi: 10.2174/156800910790980205.
9
PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.PIK3CA 外显子 20 突变作为 KRAS 野生型转移性结直肠癌抗 EGFR 单克隆抗体耐药的潜在生物标志物：系统评价和荟萃分析。
Ann Oncol. 2012 Jun;23(6):1518-25. doi: 10.1093/annonc/mdr464. Epub 2011 Oct 29.
10
A novel predictive strategy by immunohistochemical analysis of four EGFR ligands in metastatic colorectal cancer treated with anti-EGFR antibodies.一种通过免疫组化分析四种 EGFR 配体预测转移性结直肠癌接受抗 EGFR 抗体治疗效果的新策略。
J Cancer Res Clin Oncol. 2013 Mar;139(3):367-78. doi: 10.1007/s00432-012-1340-x. Epub 2012 Oct 26.
引用本文的文献
1
The Risks of miRNA Therapeutics: In a Drug Target Perspective.miRNA 治疗的风险：从药物靶点角度看。
Drug Des Devel Ther. 2021 Feb 22;15:721-733. doi: 10.2147/DDDT.S288859. eCollection 2021.
2
Precision medicine for advanced prostate cancer.晚期前列腺癌的精准医学
Curr Opin Urol. 2016 May;26(3):231-9. doi: 10.1097/MOU.0000000000000278.
本文引用的文献
1
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.结直肠癌中针对 EGFR 阻断的获得性耐药的分子进化。
Nature. 2012 Jun 28;486(7404):537-40. doi: 10.1038/nature11219.
2
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.结直肠癌中 KRAS 突变的出现和抗 EGFR 治疗的获得性耐药。
Nature. 2012 Jun 28;486(7404):532-6. doi: 10.1038/nature11156.
3
K-ras mutations and benefit from cetuximab in advanced colorectal cancer.K-ras突变与晚期结直肠癌患者从西妥昔单抗治疗中获益的关系
N Engl J Med. 2008 Oct 23;359(17):1757-65. doi: 10.1056/NEJMoa0804385.
4
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.野生型KRAS是帕尼单抗对转移性结直肠癌患者疗效所必需的。
J Clin Oncol. 2008 Apr 1;26(10):1626-34. doi: 10.1200/JCO.2007.14.7116. Epub 2008 Mar 3.
5
Cetuximab for the treatment of colorectal cancer.西妥昔单抗用于治疗结直肠癌。
N Engl J Med. 2007 Nov 15;357(20):2040-8. doi: 10.1056/NEJMoa071834.
6
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.帕尼单抗联合最佳支持治疗与单纯最佳支持治疗用于化疗难治性转移性结直肠癌患者的开放标签III期试验。
J Clin Oncol. 2007 May 1;25(13):1658-64. doi: 10.1200/JCO.2006.08.1620.
Zotero 插件